Ngm Biopharmaceuticals Stock EBITDA
NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
NGM |
NGM Biopharmaceuticals Company EBITDA Analysis
NGM Biopharmaceutica's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current NGM Biopharmaceutica EBITDA | (144.33 M) |
Most of NGM Biopharmaceutica's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NGM Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, NGM Biopharmaceuticals reported earnings before interest,tax, depreciation and amortization of (144.33 Million). This is 116.45% lower than that of the Pharmaceuticals sector and 244.1% lower than that of the Health Care industry. The ebitda for all United States stocks is 103.7% higher than that of the company.
NGM EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NGM Biopharmaceutica's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics of similar companies.NGM Biopharmaceutica is currently under evaluation in ebitda category among its peers.
NGM Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (179.78) % | |||
| Current Valuation | (36.13 M) | |||
| Shares Outstanding | 83.46 M | |||
| Shares Owned By Insiders | 21.08 % | |||
| Shares Owned By Institutions | 54.16 % | |||
| Number Of Shares Shorted | 1.68 M | |||
| Price To Earning | (21.12) X | |||
| Price To Book | 0.86 X | |||
| Price To Sales | 29.10 X | |||
| Revenue | 4.42 M | |||
| Gross Profit | (125.73 M) | |||
| EBITDA | (144.33 M) | |||
| Net Income | (142.38 M) | |||
| Cash And Equivalents | 297.81 M | |||
| Cash Per Share | 3.71 X | |||
| Total Debt | 5.38 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 7.49 X | |||
| Book Value Per Share | 1.79 X | |||
| Cash Flow From Operations | (132.2 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (1.73) X | |||
| Target Price | 1.66 | |||
| Number Of Employees | 138 | |||
| Beta | 1.26 | |||
| Market Capitalization | 128.53 M | |||
| Total Asset | 168.87 M | |||
| Retained Earnings | (724.01 M) | |||
| Working Capital | 136.36 M | |||
| Current Asset | 330.81 M | |||
| Current Liabilities | 43.69 M | |||
| Net Asset | 168.87 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |